Registry-listed formulations

rebaudioside A · mesh:C025474

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

1 source entries across 1 studies. This list may not include all unresolved or historical entries.

  • Rebaudioside ARegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Clinical Success Rate
100.0%

Based on 3 completed trials

Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Phase 1
1
33%
Not Applicable
2
67%

Phase Distribution

1

Early Stage

0

Mid Stage

0

Late Stage

Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
N/ANon-phased studies
2(66.7%)

Highest Phase Reached

Phase 1

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

3

all time

Status Distribution
Completed(3)

Detailed Status

Completed3

Development Timeline

Analytics

Development Status

Total Trials
3
Active
0
Success Rate
100.0%
Most Advanced
Phase 1

Trials by Phase

Phase 11 (33.3%)
N/A2 (66.7%)

Trials by Status

completed3100%

Recent Activity

Clinical Trials (3)

Drug Details

Intervention Type
Varies by study
Molecule Type
Oligosaccharide
Total Trials
3

External References

Names & Codes

Research Codes

E-960AFEMA NO. 4601INS NO.960AINS-960AReb-a 97